Insights from the Third Quarter 2025 13F Filing Joel Greenblatt (Trades, Portfolio) recently submitted the 13F filing for the third quarter of 2025, providing

NEW YORK , Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE: TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE: UNH) acquired Amedisys in a deal completed today.

AMED's planned merger with UnitedHealth remains on the rocks with regulatory overhang still an issue. The deal is also asymmetrically weighted in UNH's favor, with the latter up for no penalty if it fails. Not so for AMED. Aside from this, there are internal factors dragging on AMED's business performance.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amedisys (AMED) Q2 Revenue Tops 5%

Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amedisys (AMED) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to earnings of $1.32 per share a year ago.

BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025.

Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and Chemed (CHE). But which of these two stocks offers value investors a better bang for their buck right now?